VSXY

Victoria’s Secret

$94.57

-1.97%
Nov 20, 2026
Bobby Quantitative Model
Victoria's Secret & Co. is a specialty retailer of women's intimate apparel, loungewear, and beauty products, operating through its flagship Victoria's Secret and PINK brands alongside the digitally native Adore Me acquisition, with an integrated store-and-online model supported by an in-house merchandise sourcing and production function that also serves international partners. The company is the dominant incumbent in the U.S. intimate apparel category, but it occupies a contested position — a legacy mall-based powerhouse attempting to reinvent itself against nimble direct-to-consumer challengers and mass-market encroachment rather than a pure growth disruptor. The current investor narrative has shifted decisively from turnaround skepticism to a re-rating story: a decisive Q2 FY2026 earnings beat with raised guidance, gross margin expansion, and a powerful short squeeze (short ratio of 6.34) have driven a violent revaluation of the equity, while the recent B of A downgrade to Neutral from Buy signals growing debate over whether the operational recovery is now fully reflected in the price after a multi-month melt-up.

People also watch

TJX Companies

TJX Companies

TJX

Analysis
Ross Dress for Less

Ross Dress for Less

ROST

Analysis
Burlington

Burlington

BURL

Analysis
Gap Inc.

Gap Inc.

GAP

Analysis
Urban Outfitters

Urban Outfitters

URBN

Analysis

BobbyInvestment Opinion: Should I buy VSXY Today?

Rating: Hold. The core thesis is that Victoria's Secret has delivered a genuine, reported operational turnaround — ~1,160 bps of gross margin expansion, 10.4% revenue growth, and net income inflecting from $16 million to $183 million — but at $106.17 the equity has already run past the $100.33 average analyst target (roughly -5.5% implied downside) and absorbed a B of A downgrade to Neutral on Nov 12, 2026, so the risk/reward is now balanced rather than compelling. The consensus rating of "buy" (mean 2.38, 6 Buy / 7 Hold / 0 Sell) reflects residual optimism, but the price action has front-run the sell-side models.

Supporting evidence is strong on fundamentals: Q2 FY2026 gross margin of 47.18% versus 35.57% a year earlier, revenue of $1.611 billion up 10.4% YoY, net income of $183.0 million (11.4% margin) versus $16.0 million, and trailing free cash flow of $554 million ($328 million generated in Q2 alone on just $74 million of capex). Valuation is reasonable on forward numbers — 18.34x forward earnings on consensus EPS of $6.60, 0.67x sales, 1.58x EV/Sales, and 12.96x EV/EBITDA — but rich on trailing (27.26x PE) and book (5.09x PB), and the stock sits near the top of its own historical multiple band versus 10.17x PE at Q2 FY2026 reporting and 6.37x at Q4 FY2025. The 64% spread between the $73 low and $120 high target, plus a 2.13 beta and 6.34 short ratio, confirms the market is deeply divided on durability.

The three biggest risks that could invalidate the thesis are: (1) margin reversion — if the 47% gross margin slips back toward the 36.4% trailing level, most of the $183 million quarterly profit evaporates; (2) valuation compression — at 27.26x trailing and 5.09x book, multiple normalization alone could halve the price without any earnings deterioration; and (3) seasonal cash strain — Q1 FY2026 burned $191 million of FCF and Q3 FY2025 burned $232 million, with debt-to-equity at 3.32x and no dividend cushion. This Hold would upgrade to Buy if the stock pulls back toward the $90–$95 consolidation shelf or if Q3/Q4 results confirm gross margin holding above 45% with a fresh round of analyst target raises above $115; it would downgrade to Sell if gross margin falls below 40% or revenue growth decelerates below 5%. Verdict: fairly valued to modestly overvalued relative to consensus and its own history, but defensible on forward earnings if the margin recovery proves structural.

Sign up to view all

VSXY 12-Month Price Forecast

The forward view is genuinely two-sided: the reported turnaround is real — 10.4% revenue growth, $183 million of Q2 net income versus $16 million, and $554 million of trailing FCF — but the equity has already priced much of it in, trading above the $100.33 average target and near the top of its historical multiple band after a 20.1% one-month and 19.3% three-month run. The base case (50% probability, $95–$105) assumes consolidation around consensus as margin gains hold in the low-to-mid 40s without further multiple expansion, while the bull case (25%, $116–$120) requires structural margin durability and a breakout above the $116.32 high, and the bear case (25%, $73–$85) prices a holiday promotional reversion toward the $73 low target. The B of A downgrade to Neutral on Nov 12, 2026 against reiterated Overweights from Wells Fargo, Barclays, and Morgan Stanley captures the central debate over whether the recovery is fully reflected. I would upgrade to bullish if Q3 results show gross margin above 45% with analyst targets revised above $115, and downgrade to bearish if gross margin falls below 40% or revenue growth decelerates below 5%.

Historical Price
Current Price $94.57
Average Target $100.00
High Target $120.00
Low Target $73.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Victoria’s Secret's 12-month outlook, with a consensus price target around $102.00 and implied upside of +7.9% versus the current price.

Average Target

$102.00

13 analysts

Implied Upside

+7.9%

vs. current price

Analyst Count

13

covering this stock

Price Range

$73 - $120

Analyst target range

Buy
6 (46%)
Hold
7 (54%)
Sell
0 (0%)

Coverage is moderate with 12 analysts: 6 Buy, 7 Hold, and 0 Sell, yielding a consensus recommendation of "buy" (mean rating 2.38 on a 1-5 scale where lower is more bullish) and an average target price of $100.33. Against the current $106.17 price, that average target implies roughly -5.5% downside — the stock has run past the consensus fair value, a classic signal that price has outrun analyst models and that upgrades/target revisions are needed to sustain further gains. The consensus leans cautiously bullish on ratings but the price action has already overshot the average target, creating a tension that argues for consolidation or a pullback unless new catalysts emerge.

The target range of $73.00 to $120.00 is wide — a 64% spread from low to high — signaling genuine disagreement about the durability of the turnaround. The $120 high target assumes continued margin expansion toward the 47% gross margin run-rate, sustained double-digit revenue growth, and multiple expansion as the market gains confidence in the recovery; the $73 low target prices in a reversion toward historical promotional intensity, margin compression, and the risk that the current earnings surge is cyclical rather than structural. Institutional ratings show a clear pattern of recent deterioration at the margin: B of A downgraded to Neutral from Buy on Nov 12, 2026, while Wells Fargo, Barclays, and Morgan Stanley reiterated Overweight through October — the divergence between price strength and a fresh downgrade is the key signal to watch, and the wide target spread combined with a 2.13 beta and 6.34 short ratio means volatility is likely to remain elevated in both directions.

Drowning in data?

Find the real signal!

Bulls vs Bears: VSXY Investment Factors

The bull case currently has the stronger evidentiary base: a ~1,160 bps gross margin expansion, 10.4% revenue growth, net income inflecting from $16 million to $183 million, and $554 million of trailing FCF are hard, reported numbers rather than narrative. The bear case rests largely on price and positioning — the stock at $106.17 has overshot the $100.33 average target, trades near the top of its historical multiple range, and just absorbed a B of A downgrade to Neutral. The single most important tension is whether the 47% gross margin is structural (full-price selling, brand reinvention) or cyclical (freight and input cost relief, favorable promotional backdrop); if margins prove structural, the forward PE of 18.3x is cheap and the stock can grind higher, but if they revert toward the 36% trailing level, the re-rating unwinds violently given the 2.13 beta. With 7 of 12 analysts at Hold and a 64% spread between the $73 low and $120 high target, the market itself is deeply divided on this exact question.

Bullish

  • Gross margin up ~1,160 bps YoY: Q2 FY2026 gross margin reached 47.18% versus 35.57% a year earlier, a ~1,160 basis point expansion driven by full-price selling and lower promotional intensity. Q1 FY2026's 37.63% versus 35.03% confirms this is a multi-quarter trend rather than a one-off, and it is the single biggest driver of the earnings re-rating.
  • Revenue reaccelerated to 10.4% YoY: Q2 FY2026 revenue of $1.611 billion grew 10.4% over $1.459 billion in the prior-year quarter, a sharp inflection from the roughly flat FY2025 trajectory. Because the company reports as a single segment, the growth is broad-based across intimates, PINK, and beauty rather than dependent on one product line.
  • Net income inflected from $16M to $183M: Q2 FY2026 net income of $183.0 million (11.4% net margin) versus $16.0 million a year earlier, with operating income of $259.8 million (16.1% margin) versus $41.0 million (2.8%). The company swung from a Q3 FY2025 net loss of $37 million to double-digit revenue growth and healthy run-rate profitability within a year.
  • Strong FCF and idiosyncratic momentum: Trailing free cash flow is $554 million, and Q2 FY2026 alone generated $328 million of FCF on $402 million of operating cash flow against just $74 million of capex. Meanwhile VSXY outperformed SPY by 22.38 points over one month and 22.10 points over three months while the S&P fell 2.26% and 2.83%, signaling genuine alpha rather than beta drift.

Bearish

  • Price has overshot consensus target: The $106.17 price sits above the $100.33 average analyst target, implying roughly -5.5% downside to consensus fair value. With 7 of 12 analysts at Hold and a mean rating of 2.38, the ratings lean cautiously bullish while the price action has already run past analyst models, requiring fresh upgrades to sustain gains.
  • B of A downgrade signals re-rating done: B of A downgraded VSXY to Neutral from Buy on Nov 12, 2026, even as Wells Fargo, Barclays, and Morgan Stanley reiterated Overweight through October. The divergence between price strength and a fresh downgrade suggests the easy money in the multiple expansion has been made.
  • Valuation near top of historical band: The PE ratio was 10.17x at Q2 FY2026 reporting and 6.37x at Q4 FY2025 versus 27.26x today, and PB sits at a rich 5.09x on a thin equity base. The stock now trades near the top of its own historical valuation range on most measures, leaving little room for execution missteps.
  • Leverage and seasonal cash burn: Debt-to-equity of 3.32x is elevated for a retailer and the current ratio of 1.25 is only adequate. Cash flow is highly seasonal — Q1 FY2026 burned $191 million of FCF and Q3 FY2025 burned $232 million — so the company depends on Q2/Q4 harvests to fund the year with no dividend cushion.

VSXY Technical Analysis

VSXY is in a powerful, sustained uptrend, with the stock at $106.17 sitting roughly 91% of the way through its 52-week range of $33.61 to $116.32 — a positioning that screams momentum leadership rather than value opportunity. The magnitude of the move is extraordinary: the shares have more than tripled off the 52-week low, and the current price is only about 9% below the 52-week high, meaning the stock is pressing against the upper boundary of its range with little overhead supply. This is the profile of an overextended but institutionally sponsored momentum name, where pullbacks have been aggressively bought rather than signaling distribution.

Short-term momentum is accelerating rather than fading, with a 1-month gain of 20.12% and a 3-month gain of 19.27% stacking on top of the longer advance — a rare pattern where the recent trend is as strong as the intermediate trend, indicating no loss of thrust. The relative strength figures are the real tell: VSXY has outperformed SPY by 22.38 percentage points over one month and 22.10 points over three months, while the S&P itself was down 2.26% and 2.83% over those same windows — this is genuine idiosyncratic alpha, not beta-driven drift. The most recent week shows a modest cooling (from $113.52 on Nov 9 to $106.17 on Nov 13, a pullback of about 6.5% from the local peak), consistent with profit-taking after a parabolic run rather than a trend break.

Key technical levels are well defined: resistance sits at the $116.32 52-week high, and a clean breakout above that level would confirm the uptrend's continuation and likely trigger another leg of momentum-chasing and short covering. Support is anchored by the $33.61 52-week low, but far more relevant near-term support lies in the $95–$100 zone where the stock consolidated in late October before its November breakout — a break below that shelf would signal the first meaningful crack in the trend. The beta of 2.127 is critical for risk management: VSXY is more than twice as volatile as the market, meaning a 10% SPY drawdown could translate into a 20%+ hit here, so position sizing must be materially smaller than a market-beta equivalent, and the 6.34 short ratio adds squeeze fuel in both directions.

Beta

2.13

2.13x market volatility

Max Drawdown

-27.4%

Largest decline past year

52-Week Range

$36-$116

Price range past year

Annual Return

—

Cumulative gain past year

PeriodVSXY ReturnS&P 500
1m+6.1%-9.7%
3m+10.8%-9.9%
6m—-7.5%
1y—+4.7%
ytd—+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

VSXY Fundamental Analysis

The revenue trajectory has inflected decisively upward: Q2 FY2026 revenue of $1.611 billion grew 10.4% year-over-year against $1.459 billion in the prior-year Q2, a sharp acceleration from the roughly flat-to-modest growth seen through FY2025 (Q1 FY2026 revenue of $1.560 billion versus $1.353 billion a year earlier, and Q4 FY2025's $2.269 billion versus $2.106 billion). The company operates as a single reportable segment at $1.611 billion, so the growth is broad-based across intimates, PINK, and beauty rather than driven by one line, which strengthens the durability of the recovery case. This reacceleration — from a business that posted a net loss in Q3 FY2025 to one now compounding double digits — is the core of the bull thesis and explains the violent re-rating.

Profitability has transformed: Q2 FY2026 net income of $183.0 million (an 11.4% net margin) versus just $16.0 million a year earlier, with gross margin expanding to 47.18% from 35.57% — a staggering ~1,160 basis point improvement that reflects full-price selling, lower promotional intensity, and freight/input cost relief. Operating income of $259.8 million (16.1% operating margin) compares to $41.0 million (2.8%) in the prior-year quarter, and the Q1 FY2026 gross margin of 37.63% versus 35.03% confirms the expansion is a multi-quarter trend, not a one-off. The trailing net margin of 2.46% and operating margin of 4.14% look thin only because they still carry the drag of the loss-making Q3 FY2025; the run-rate profitability is far healthier, and the 36.4% trailing gross margin understates the current 47%+ reality.

Balance sheet and cash flow are the weak spot relative to the income statement: debt-to-equity of 3.32x is elevated for a retailer, the current ratio of 1.25 is adequate but not comfortable, and the company carries meaningful lease-adjusted leverage. Positively, trailing free cash flow is $554 million and Q2 FY2026 alone generated $328 million of FCF on $402 million of operating cash flow against just $74 million of capex, while ROE of 18.8% and ROA of 6.5% are respectable. The cash flow is highly seasonal — Q1 FY2026 burned $191 million of FCF and Q3 FY2025 burned $232 million — so the company depends on the Q2/Q4 harvest to fund the year, and with $522 million of cash at Q2-end and no dividend (payout ratio of 0), internal funding is sufficient but leaves limited cushion if the turnaround stumbles.

Quarterly Revenue

$1.6B

2026-08

Revenue YoY Growth

+10.4%

YoY Comparison

Gross Margin

47.2%

Latest Quarter

Free Cash Flow

$554000000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Reportable Segment

Open an Account, get $2 TSLA now!

Valuation Analysis: Is VSXY Overvalued?

Because net income is positive, the PE ratio is the appropriate primary metric: VSXY trades at 27.26x trailing earnings but only 18.34x forward earnings, a roughly 33% compression that implies the market expects earnings to grow substantially — consistent with consensus EPS estimates of $6.60 versus the trailing $0.037 figure that is distorted by the loss-making quarter in the trailing window. The forward PE of 18.3x on $6.60 of estimated EPS against a $106.17 price is the cleaner read, and the gap between trailing and forward multiples signals the market is underwriting continued margin-driven earnings recovery rather than paying for past results.

Against the broader apparel retail sector, the picture is mixed: the PS ratio of 0.67x and EV/Sales of 1.58x are modest for a retailer with double-digit growth and 47% gross margins, but the PB ratio of 5.09x is rich and reflects the thin equity base created by the leveraged balance sheet. The EV/EBITDA of 12.96x is reasonable for a turnaround with this momentum, and the PEG ratio of -11.17 is not meaningful given the negative trailing earnings base. On balance, VSXY is not cheap on book or trailing earnings but looks reasonably valued on forward earnings and sales relative to its improved growth and margin profile — the premium is defensible if the 10%+ revenue growth and 47% gross margins prove sustainable.

Historically, the stock's own valuation band has compressed dramatically: the PE ratio was 10.17x at Q2 FY2026 reporting and 6.37x at Q4 FY2025, versus 27.26x today, while the PS ratio has risen from 2.06x at Q4 FY2025 to the current 0.67x on a much larger market cap base — the multiple expansion is the story of the past year. The stock now sits near the top of its historical valuation range on most measures, which means the market is pricing in optimistic expectations and leaves little room for execution missteps; the recent B of A downgrade to Neutral reflects exactly this concern that the easy money in the re-rating has been made.

PE

27.3x

Latest Quarter

vs. Historical

High-End

5-Year PE Range 4x~24x

vs. Industry Avg

20.5x

Industry PE ~20.5x*

EV/EBITDA

13.0x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on leverage and margin durability. Debt-to-equity of 3.32x is elevated for an apparel retailer, and the current ratio of 1.25 offers only modest liquidity headroom. The 47.18% Q2 gross margin is the linchpin of the entire thesis — a reversion toward the 36.4% trailing gross margin would erase most of the $183 million quarterly net income, and the business is highly seasonal, with Q1 FY2026 burning $191 million of FCF and Q3 FY2025 burning $232 million, meaning a weak Q4 harvest would strain the $522 million cash position. Revenue is also concentrated in a single reportable segment and a U.S. mall-based store base, exposing results to consumer discretionary spending and foot traffic. Market and competitive risks are dominated by valuation compression and brand relevance. The stock trades at 27.26x trailing and 5.09x book versus historical PE of 10.17x at Q2 FY2026 and 6.37x at Q4 FY2025, so multiple compression alone could halve the price without any earnings deterioration. A beta of 2.127 means VSXY amplifies market moves more than twofold, and the 6.34 short ratio makes both rallies and selloffs self-reinforcing. Competitively, nimble DTC challengers and mass-market encroachment continue to pressure the legacy mall model, and the B of A downgrade to Neutral on Nov 12, 2026 highlights that sell-side conviction is already fraying at the margin. The worst-case scenario is a margin-reversion chain: holiday promotions intensify, Q4 gross margin slips back toward the high-30s, the market re-prices the stock on trailing rather than forward earnings, and the short squeeze unwinds in reverse. The $73 analyst low target implies roughly -31% from $106.17, and a fuller reversion toward the pre-re-rating valuation band or the $33.61 52-week low would be catastrophic, though the more realistic downside is a -25% to -31% drawdown to the $73–$80 zone where the stock traded as recently as September 2026. Given the 2.13 beta, a broad market correction could compound this to -40% or worse.

FAQ

The most severe risk is margin reversion: the 47.18% Q2 gross margin is the linchpin of the thesis, and a slide toward the 36.4% trailing level would erase most of the $183.0 million quarterly net income, with the $73 analyst low target implying roughly -31% downside. Second is valuation compression — at 27.26x trailing earnings and 5.09x book, multiple normalization alone could halve the price without any earnings deterioration, especially given the historical PE band of 6–10x. Third is financial and seasonal strain: debt-to-equity of 3.32x is elevated, the current ratio of 1.25 is only adequate, and cash flow is highly seasonal (Q1 FY2026 burned $191 million of FCF, Q3 FY2025 burned $232 million), with no dividend cushion. Fourth is market and competitive risk — a beta of 2.127 means a 10% S&P drawdown could translate into a 20%+ hit, the 6.34 short ratio makes moves self-reinforcing in both directions, and nimble DTC challengers plus mass-market encroachment continue to pressure the legacy mall-based model.

The 12-month outlook splits into three scenarios. The base case carries 50% probability with a $95–$105 target range, assuming the stock consolidates around the $100.33 average analyst target as gross margin holds in the low-to-mid 40s, revenue grows high single digits, and forward PE stays near 15–16x on $6.60 of consensus EPS. The bull case (25% probability, $116–$120) requires structural margin durability — Q3 gross margin above 45%, holiday full-price sell-through, and a breakout above the $116.32 52-week high that triggers short covering toward the $120 high target. The bear case (25% probability, $73–$85) prices a holiday promotional reversion that pushes Q4 gross margin toward the high-30s and re-prices the stock on trailing earnings toward the $73 low target. The base case is most likely, and its key assumption is that the margin recovery holds without further multiple expansion — meaning the stock is more likely to consolidate than to extend its 20.1% one-month gain.

The answer depends heavily on which multiple you anchor to. On trailing earnings, VSXY looks expensive at 27.26x PE and 5.09x book, and the stock trades near the top of its own historical band — the PE was 10.17x at Q2 FY2026 reporting and 6.37x at Q4 FY2025. On forward earnings, however, the 18.34x multiple on $6.60 of consensus EPS represents roughly 33% compression from trailing, and the 0.67x PS and 1.58x EV/Sales are modest for a retailer with double-digit growth and 47% gross margins, while 12.96x EV/EBITDA is reasonable for a turnaround. The market is therefore pricing in continued margin-driven earnings recovery rather than paying for past results, which is defensible if the 47% gross margin proves structural. Net verdict: fairly valued to modestly overvalued relative to consensus and its own history, but not egregiously priced on forward numbers — the premium is earned only if the recovery holds.

From a pure risk/reward standpoint, VSXY is a balanced rather than compelling buy at $106.17. The fundamentals are genuinely improved — Q2 FY2026 gross margin of 47.18% versus 35.57%, revenue growth of 10.4%, and net income of $183.0 million versus $16.0 million — and the forward PE of 18.34x on $6.60 of consensus EPS is not demanding for that trajectory. However, the price already sits above the $100.33 average analyst target (roughly -5.5% implied downside), 7 of 12 analysts rate it Hold, and B of A downgraded to Neutral on Nov 12, 2026, suggesting the easy re-rating gains have been captured. The biggest downside risk is margin reversion: a slide back toward the 36.4% trailing gross margin would erase most of the quarterly profit and could take the stock toward the $73 low target, roughly -31%. It is a reasonable buy for investors with a 12–24 month horizon who can tolerate a 2.13 beta and who accumulate on a pullback toward the $90–$95 shelf, but it is not an attractive entry at current levels for the risk-averse.

VSXY is better suited to a medium-to-long-term holding than to short-term trading, but only for investors who can stomach significant volatility. The company is in a genuine turnaround with improving fundamentals — 10.4% revenue growth, 47.18% gross margin, $554 million of trailing FCF, and 18.8% ROE — which supports a 12–24 month thesis if the margin recovery proves structural. However, the beta of 2.127, the 6.34 short ratio, and the 64% spread between the $73 low and $120 high analyst targets mean near-term price action will be violent in both directions, and the stock has already run 20.1% in one month and 19.3% in three months, so chasing at $106.17 is risky. There is no dividend (payout ratio of 0) to cushion the wait, and earnings visibility is limited by seasonal cash swings. A concrete suggested minimum holding period is 12 months, ideally entered on a pullback toward the $90–$95 consolidation shelf, with position sizing materially smaller than a market-beta equivalent given the 2.13 beta.